Neurosense Therapeutics is trading 7.51% lower at $2.09, with no clear company-specific announcement explaining the October 29, 2026 decline identified in available search results. - The Nasdaq Composite is down 1.48%; broader market weakness may be contributing, but the specific catalyst remains uncertain. - Recent coverage of the Nasdaq listing hearing and PrimeC collaboration predates the session and does not establish a cause.